urologytimes2d
How recombinant BCG could ease strain of supply issues
"I'm all for this great effort by ImmunityBio to provide us with an alternative option,” says Suzanne B. Merrill, MD, FACS. For years, urologists and patients have dealt with the effects of the BCG ...
urologytimes2d
BPH: The Patient Journey
A panelist discusses how benign prostatic hyperplasia (BPH) management involves a comprehensive patient journey that encompasses initial diagnostic evaluation, tailored pharmacological interventions ...
urologytimes2d
Suzanne B. Merrill, MD, FACS
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...
urologytimes2d
John J. Mulcahy, MD, PhD
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...
urologytimes3d
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
"Viral vectors are basically a blueprint of the virus that's used to carry the DNA payload into the target tissue, but the problem is they have some issues," says Katherine Chan, MD, MPH. Detalimogene ...
urologytimes4d
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate ...
urologytimes5d
FDA grants marketing authorization to at-home diagnostic test for STIs
The Visby Medical test is the first at-home, prescription-free diagnostic for chlamydia, gonorrhea, and trichomoniasis. It provides results in approximately 30 minutes using a self-collected vaginal ...
urologytimes5d
Pain management disparities in kidney stones point to need for guidelines, experts say
"For other health care professionals aiming to advocate for equitable changes within their system, it's really important to just start conversations about what you're noticing," says Hailey Frye.
urologytimes5d
FDA testosterone labeling changes: How will they affect prescribing?
"In a practice like mine, where approximately 30% of the practice is low testosterone, it'll have actually very little negative effect," says John P. Mulhall, MD. Following the FDA’s class-wide ...
urologytimes5d
FDA approves expanded label for 177Lu-PSMA-617 in mCRPC
177Lu-PSMA-617 is now approved for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. The phase 3 PSMAfore trial showed a 59% reduction in radiographic progression or ...
urologytimes5d
FDA approves durvalumab/chemo for muscle–invasive bladder cancer
The FDA approved neoadjuvant durvalumab with gemcitabine and cisplatin, followed by adjuvant durvalumab, for muscle invasive bladder cancer (MIBC). Phase 3 NIAGARA trial results showed improved ...
urologytimes5d
John Taylor, III, MD, on novel options in NMIBC
John A. Taylor, III, MD, MS, discussed the new wealth of options in non–muscle invasive bladder cancer, specifically highlighting detalimogene voraplasmid. In a recent interview with Urology Times®, ...